[EASL2012]EASL会议亮点及EASL慢性HBV感染管理临床实践指南——EA

StephenW

[EASL2012]EASL会议亮点及EASL慢性HBV感染管理临床实践指南——EASL2012秘书长Mark Thursz教授访谈            

-----

            

来源： 作者：Mark Thursz 发布时间：2012-4-24 15:34:48   阅读：235

                                    
            　　英国伦敦帝国理工学院Mark Thursz教授：2011 EASL副秘书长，EASL现任秘书长。Thursz教授是著名的肝脏病学家，主要的研究领域包括病毒性肝炎、酒精性肝病以及脂肪肝等。他在病毒性肝炎感染及脂肪肝的自然史和有关决定慢性感染与恶性肝病进展的危险因素的研究中做了突出贡献，并推动了基因联合、基因组学扫描在有关致病性基因突变的研究中的应用。目前他正从事有关慢性乙型肝炎感染的向肝癌慢性进展过程的研究工
                                               
                                                      

　　英国伦敦帝国理工学院Mark Thursz教授：2011 EASL副秘书长，EASL现任秘书长。Thursz教授是著名的肝脏病学家，主要的研究领域包括病毒性肝炎、酒精性肝病以及脂肪肝等。他在病毒性肝炎感染及脂肪肝的自然史和有关决定慢性感染与恶性肝病进展的危险因素的研究中做了突出贡献，并推动了基因联合、基因组学扫描在有关致病性基因突变的研究中的应用。目前他正从事有关慢性乙型肝炎感染的向肝癌慢性进展过程的研究工
　　Hepatology Digest: There are 7 Joint Workshops that ran parallel the morning of the first day of this year’s EASL. The workshops EASL-HepaCute & SPHINX and EASL-VIRGIL (European Surveillance Network for Vigilance Against Viral Resistance) are both about viral hepatitis. Could you discuss briefly the aim and significance of the two projects? And their progress？
　　《国际肝病》：今年EASL的第一天上午有7个共同研讨会亮相，其中的EASL-HepaCute & SPHINX和EASL-VIRGIL（欧洲病毒耐药预警监测网）的工作都是关于病毒性肝炎的。请您简要介绍这两个项目的研究目标和意义，以及目前的进展。
　　Professor Thursz: Some of the workshops that we run at the beginning of the conference come out of consortiums that EASL has sponsored or supported in one way or another. VIRGIL was one of the first and biggest of these. It was a project that began in 2004 looking at antiviral resistance particularly hepatitis B but also flu. The European Commission on an FP6 grant supported it. It was so successful and so popular that we have continued to run it even after the end of the grant.
　　Thursz教授：在本次EASL开幕伊始亮相的部分研讨会是由EASL通过不同方式启动或赞助进行的。VIRGIL是其中第一项也是最大的一项计划，开始于2004年，旨在检测病毒耐药，尤其是乙型肝炎病毒（HBV），但也包括流感病毒，受欧洲委员会FP6基金资助。VIRGIL计划十分成功，也很受欢迎，因此在基金资助结束后EASL仍然继续运行了这一计划。
　　Now there are two FP7 European Commission grants in hepatitis C focusing on acute hepatitis C with some link in each project to Egypt where of course the prevalence of infection is very high. One of these grants is for HepaCute， one that I am particularly involved in and the other one is SPHINX. Now because they share similar topics， they have run two joint workshops， the second of which was held this year.
　　目前有两项聚焦急性丙型肝炎的欧洲委员会FP7丙型肝炎基金，他们与丙肝病毒感染高发的埃及的项目都有联系。其中之一就是HepaCute，我也是该项目的参与者，另一项计划名为SPHINX。他们的主题很相似，主办了两次共同的研讨会，第二次探讨会就是今年召开的。
　　Hepatology Digest: There is another Joint Workshop called the EASL-CHINA NETWORK on the first day. How would you describe the target of this thematic session? What future cooperation do you envision between EASL and China?
　　《国际肝病》：EASL首日还有一个共同研讨会，名为EASL-CHINA网，您对这一专题会议如何评价，您如何看待对EASL和中国合作的未来？
　　Professor Thursz: We have had a number of approaches over the years to set something a little different for delegates to come to the International Liver Congress from China. Some Chinese delegates find it perhaps a little difficult or overwhelming with all the sessions during the rest of the congress that run in English with no translation. There are also obviously some special aspects of hepatology and hepatitis B and liver cancer care that are unique to China particularly specific genotypes of the hepatitis B virus. So what we wanted to do was provide a workshop with simultaneous translation that would be very accessible to Chinese delegates. This was an incredibly successful event. We received some very positive feedback from it so we will be looking to continue to do this in future International Liver Congress meetings.
　　Thursz教授：近年来，我们已有很多途径为中国代表团提供参与国际肝病大会的机会。一些中国代表可能会遇到一些困难，可能会超过其他英语为工作语言又没有翻译的会议。同样，很明显，在肝病、乙型肝炎和肝癌治疗方面，有些问题是中国独有的，尤其是HBV基因型。因此，我们所做的是为中国代表团提供一个同传小组，这无疑是一个成功的举措，我们收到了一些非常正面的反馈，因此在今后的国际肝病会议我们希望会继续这样做。
　　Hepatology Digest: Would you talk about some of the highlights in this year’s EASL ?
　　《国际肝病》：能否介绍一下本次EASL的一些亮点？
　　Professor Thursz: That is quite difficult! There are so many great things that went on this year.
　　Thursz教授：这个很难。今年的EASL精彩内容太多。
　　For those involved in the treatment of patients with hepatitis C， there are several new oral and poster presentations on interferon free regimens. We can now see that interferon free regimens will be available outside of clinical trials in a couple of years and that this is very exciting.
　　有一些关于丙型肝炎病毒感染患者的无干扰素治疗防范的新的大会报告和海报。我们可以从中看到，无干扰素方案将在几年没应用于临床，这是非常令人兴奋的进展。
　　There is also some interesting new data on fatty liver disease， which occurs worldwide with particular importance in Europe. There was an abstract showing that childhood obesity predicts a risk of developing cancer through NASH. The number of cancers in patients with NASH appears to be increasing even in patients that appear to not to be cirrhotic.
　　关于脂肪性肝病也有一些非常有趣的新的研究，脂肪性肝病在全世界尤其是欧洲十分盛行，有一篇摘要提到，儿童期肥胖可预测经由NASH进展为肝癌的风险。合并NASH的肝癌患者正在增加，而且有些患者并无肝硬化。
　　We are quite pleased that the EASL CLIF Consortium， which is a consortium of researchers focused on cirrhosis complications in chronic liver failure that has produced a big abstract this time on looking at acute-on chronic liver failure. It is quite pleasing that they have received a grant now to do some interventional studies to see if the prognosis of these patients can be improved. As all of us deal with patients with chronic liver failure， this is an important development.
　　我们很高兴地看到EASL CLIF组织这次会议上提交了一份关于慢加急肝衰竭的长篇摘要，这是一个专门研究慢性肝衰竭合并肝硬化的组织，令人十分兴奋的是，他们获得了基金资助，进行一些国际性研究并观察是否可改善慢加急肝衰竭患者的预后。我们都是进行慢性肝衰竭研究的，因此这篇摘要非常重要。
　　Hepatology Digest: This April， the new edition of EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection has been published. What are some of differences compared to the previous edition?
　　《国际肝病》：今年4月，新版EASL临床实践指南：慢性乙型肝炎病毒感染治疗已经出版，请问新版与旧版相比有哪些不同？
　　Professor Thursz: Inevitably the new guidelines have not changed the management of HBV too much. However， we now recognize the importance of longer term follow up in the care of patients with chronic HBV infection. There are modified recommendations on the intervals for monitoring viral loads and renal function. In assessing patients with chronic HBV infection we have emphasized the need to take age into account particularly when deciding on treating a patient with immune-tolerant disease. There are guidelines on the use of nucleos(t)ide analogues in pregnant women and we have incorporated the use of HBsAg levels into the monitoring of patients on treatment.

　　新指南中　　关于HBV的管理并未改变太多。但是，我们已经认识到了长期随访慢性HBV感染患者的重要性。新指南在监测病毒载量和肾功能的时间间隔上有些修订意见。在评估慢性HBV感染患者时，我们要重点强调当确定免疫耐受疾病患者的治疗决策时，应将年龄考虑在内。关于妊娠妇女核苷（酸）类似物的应用也有了指南。我们已经将HBsAg水平用于在治患者的监测。